Brand names

• Veklury

Indications 

Veklury (remdesivir) is FDA approved for use in adults and pediatric patients ≥12 years of age and weighing ≥40 kg requiring hospitalization for COVID-19.

For information about emergency use in hospitalized pediatric patients <12 years of age weighing at least 3.5 kg or weighing 3.5 kg to <40 kg, please see the EUA Fact Sheet and FDA Letter of Authorization available at gilead.com/remdesivir.

Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care.

Dosage Forms and Strengths

Veklury (remdesivir) 100 mg powder for concentrate for solution for infusion.

• For injection: 100 mg of remdesivir as a lyophilized powder for concentrate for solution, in a single-dose vial.

• Injection: 100 mg/20 mL (5 mg/mL) remdesivir, in a single-dose vial.

Contraindications

VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any of its components.